Clostridial myonecrosis is a life-threatening bacterial infection. It typically develops after a trauma or injury, especially in cases where the injury causes tissue death or low oxygen flow to the tissues. The infections that form in tissue with little to no oxygen tend to spread very quickly, with severe cases resulting in death within one day of infection. HBOT treatments, sometimes alongside antibiotics, can make a big difference. HBOT is an FDA-approved treatment option for Clostridial Myonecrosis, which essentially floods the infected tissue with oxygen, destroying the oxygen-deprived environment that allows the bacteria to thrive. In many cases it can increase the survival rate, allow for maximum tissue preservation, and help to avoid amputations.
